Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHAA4549A in healthy volunteers
NCT02284607Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vedolizumab in Influenza A (IAV) (3 arms), sponsored by Genentech. Primary endpoints: Incidence and nature of adverse events at 120 days, Changes in vital signs at 120 days and 2 more. Started Nov 2014; status: completed.
02
Drugs
vedolizumab
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02284607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284607.